[5]Erika Paige Hamilton et al., Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.. JCO 38, 3093-3093(2020).DOI:10.1200/JCO.2020.38.15_suppl.3093 [6]Krop IE,...
PURPOSE: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is bei...
KEY OBJECTIVE: This study aims to evaluate the tolerability and efficacy of an investigational human epidermal growth factor receptor 3 (HER3)-targeted antibody-drug conjugate (ADC; HER3-DXd) in HER3-expressing breast cancer and represents the first comprehensive analysis of HER3-DXd in patients ...
Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol. 2007;39(5):851–6.Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol. 2007; 39 (5):851–856. doi: 10.1016/j.biocel.2006.11.0...
HER3蛋白&抗体&细胞株&CDX切片 HER3先导抗体分子研究进展 参考文献：[1]Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlohner S, et al. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers (Basel). 2019;11(12).[2...
[11]Xu Z, Guo D, Jiang Z, et al. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019 Dec 1;183:111682. ...
Albanell J, Lassen U, Cortes J, Dieras V, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs 2018;36(5):...
New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer.Yasar Ahmed|Thamir Mahgoub|Maha Al Sindi|José J. Berenguer‐Pina MedComm – Oncology. 2022;e19.doi:10.1002/mog2.19...
OT3-06-01: SHERBOC: A double-blind, placebocontrolled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy. Cancer Res 2018;...
[6]Hutcheson IR, Goddard L, Barrow D, et al. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin b1. Breast Cancer Res. 2011;13(2):R29 [8]Ogden A, Bhattarai S, Sahoo B, et al. Combined HER3-EGFR score in...